newsfilter
← Latest News
GlobeNewswire·

NewcelX Announces Pricing of $1.55 Million Equity Financing at 20% Premium Pricing to Market

  • NewcelX Ltd. (Nasdaq: NCEL) announced a private placement at $3.29 per share, representing a 20% premium to the November 6, 2026 closing price.
  • The company is selling 471,125 common shares alongside warrants to purchase an additional 353,344 shares at an exercise price of $3.75 per share.
  • The offering includes existing shareholders and is expected to close on or around November 23, 2026, subject to customary conditions.
  • Net proceeds will primarily advance NCEL-101 in collaboration with Eledon Pharmaceuticals, specifically to initiate FDA-required IND-enabling toxicology studies, enhance cell manufacturing, and prepare for a Phase 1/2a trial in 2027.
  • CEO Ronen Twito highlighted the investment as a strong vote of confidence in the company's technology, strategy, and clinical potential.
  • The securities were issued under Section 4(a)(2) of the Securities Act of 1933 and Regulation D, meaning they are unregistered and restricted from public sale.
  • NewcelX is a clinical-stage biopharmaceutical company developing stem-cell-derived therapies for Type 1 Diabetes, with NCEL-101 as its lead program.
Company
NewcelX Ltd.
Keywords
Nasdaq:NCEL, NewcelX Ltd.